Navigation Links
Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
Date:4/23/2009

LEVANGER, Norway, April 23 /PRNewswire/ -- HUNT Biosciences, the commercial arm of the HUNT Study and associated biobank today announced the appointment of former GE Healthcare director Per Foss as its new CEO. The company provides pharmaceutical and healthcare companies with biomarker discovery and validation services. These are based on the unique HUNT Study, which for the past 25 years has gathered blood samples from the general population of the Nord-Trondelag region together with detailed phenotype and environmental data. Foss joins just as recruitment for the third phase, HUNT III has closed, again with an astonishing high inclusion rate of 60%. This will bring the total recruitment number of unique individuals to 135,000 and reinforce the core strengths in key public health areas such as cancer, cardiovascular disease, diabetes, obstructive lung disease, osteoporosis and mental health. More than 60 % of the participants have been screened twice, 25 % have participated in all three surveys.

"For both pharmaceutical and biotech companies, HUNT Biosciences is ideally positioned to devise biomarker strategies across a wide range of key disease areas," says Foss. "The unique combination of biomedical and phenotypic information collected over the past 25 years from a general population rather than specific cohort promises rapid and effective biomarker discovery and validation."

The HUNT Study operates as a satellite to the Norwegian University of Science and Technology (NTNU) . Per Ivar Maudal, Executive Director for innovation and industrial relations at NTNU and chairman of the board of HUNT Biosciences, welcomes the appointment: "For academic researchers HUNT already provides data on a large number of diseases observed in this general population. It has been validated by more than 45 completed PhD-degrees and several hundred ongoing or completed research projects with particular emphasis on major disease areas such as type II diabetes, osteoporosis, cancer, cardiovascular, kidney and lung diseases, We believe HUNT Biosciences provides an efficient and ethical vehicle for industry to access this data and can lead to the development of new diagnostics and therapeutics for benefit of both the Norwegian and international healthcare systems."


'/>"/>
SOURCE HUNT Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
2. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
3. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
4. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
5. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
6. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
7. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
8. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
9. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
10. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
11. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug ... Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( ... expected to deliver therapeutic levels of olanzapine for a period of 3 months., “We ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... 2017 Symic Bio, a biopharmaceutical company focused ... of therapeutics, announced today the completion of enrollment for ... disease. The trial will evaluate the safety and efficacy ... reduction of restenosis following angioplasty. "We,re ... SB-030," said Nathan Bachtell , M.D., Chief Medical ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
Breaking Biology News(10 mins):